LIPO

Lipella Pharmaceuticals Inc. Common Stock

LIPO, USA

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

https://lipella.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
LIPO
stock
LIPO

Aug Opening: Is AMAL impacted by rising rates - July 2025 Sentiment & Low Risk High Reward Ideas baoquankhu1.vn

Read more →
LIPO
stock
LIPO

Aug Momentum: Will NINE benefit from rate cuts - July 2025 Drop Watch & Low Risk Profit Maximizing Plans baoquankhu1.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$10

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.00

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-84.30 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-53.37 %

Low 2%

High 10%

Debt to Equity

-

High

0.58

Low 1

High 0.3

Investors

* Institutions hold a combined 0.26% of the total shares of Lipella Pharmaceuticals Inc. Common Stock

1.

Fidelity Extended Market Index

(0.1293%)

since

2025/05/31

2.

Vanguard Institutional Extnd Mkt Idx Tr

(0.0966%)

since

2025/05/31

3.

Fidelity Series Total Market Index

(0.03%)

since

2025/05/31

4.

Tower Research Capital LLC

(0%)

since

2025/06/30

5.

Mccormack Advisors International

(0%)

since

2025/06/30

6.

Virtu Financial LLC

(0%)

since

2025/03/31

7.

Bank of America Corp

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0

Latest Release

Date

2025-09-30

EPS Actual

-0.28

EPS Estimate

0

EPS Difference

-0.28

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(5.5)
Net Net
Strong Net-Net(8)
Quality
Low Quality Business(2.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.